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Schizophrenia is a severe neuropsychiatric disorder that affects cognition 
and behavior, however, scientists do not fully understand the underlying 
mechanisms of the disorder. Scientists have developed preclinical methods to 
study behavioral and neurochemical changes underlying schizophrenia. 
Pharmacological animal models of schizophrenia, in which neurotransmitters are 
manipulated by drugs, were developed to investigate positive and negative 
symptoms and cognitive dysfunction associated with schizophrenia.  
Acute and subchronic ionotropic glutamate receptor blockade, by 
ketamine, induces changes in central dopamine and glutamate circuits, which 
models positive and negative symptoms and cognitive dysfunction associated 
with schizophrenia in animals. Nicotine evokes dopamine release through 
activation of nicotinic acetylcholine receptors and temporarily improves negative 
symptoms and cognitive dysfunction associated with schizophrenia in animals. 
Taken together, this suggests a common underlying neurobiology between 
schizophrenia and nicotine addiction.  
The purpose of these experiments was to investigate the role of nicotine in 
schizophrenia. In the present study, ketamine did not alter dopamine release in 
rat brain. In an acute model of schizophrenia, ketamine increased nicotine-
evoked dopamine release in rat brain. In a subchronic model of schizophrenia, 
ketamine lowered the concentration of nicotine to evoke dopamine release in rat 
brain. Taken together, ketamine altered rat brain neurocircuitry which increased 
the sensitivity to nicotine. Overall, these data support a role for nicotinic receptors 
in schizophrenia treatment.  
Beyond schizophrenia, our findings suggest that the integration of multiple 
neurotransmitter systems could contribute to underlying pathophysiology of 
disorders and investigating neurotransmitter systems comprehensively could be 
valuable for treatment research. 
 
